Molina‐Vila et al22 reported that a TP53 mutation was an independent predictor of shorter survival in patients with advanced NSCLC (stage IIIB‐IV), but they did not provide the data for patients with surgically resected early‐stage NSCLC. Here, TP53 is linked to non-small cell lung carcinoma.